Next Article in Journal
Perilla frutescens: A Rich Source of Pharmacological Active Compounds
Previous Article in Journal
Development and Validation of a Method of Liquid Chromatography Coupled with Tandem Mass Spectrometry for Quantification of ST-246 (Tecovirimat) in Human Plasma
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18

1
Research Group of Drug Development, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany
2
Department of Clinical Pharmacy, Institute of Pharmacy, Ernst Moritz Arndt University Greifswald, 17489 Greifswald, Germany
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(11), 3575; https://doi.org/10.3390/molecules27113575
Submission received: 11 March 2021 / Accepted: 14 April 2022 / Published: 2 June 2022
The authors would like to correct an error made through no fault of their own in the title paper [1]. The error is related to the FAR values in Table 1. In the earlier published version, the FAR values of compounds 1521 were wrongly printed. So, they had to be corrected, from 1.19 to 1.12 for 15, 1.55 to 1.19 for 16, 0.95 to 1.55 for 17, 1.22 to 0.95 for 18, 0.98 to 1.22 for 19, 1.30 to 0.98 for 20 and 0.82 to 1.30 for 21. We provide below the corrected Table 1. The change has no influence on the reported results. The original article has been updated. The authors would like to apologize for any inconvenience caused to the readers by this change.

Reference

  1. Döring, H.; Kreutzer, D.; Ritter, C.; Hilgeroth, A. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18. [Google Scholar] [CrossRef] [PubMed]
Table 1. MRP4 inhibition data of target compounds 421 with varied substitution patterns expressed as FAR values.
Table 1. MRP4 inhibition data of target compounds 421 with varied substitution patterns expressed as FAR values.
CompoundR1R2R3R4FAR
Value [a]
4CF3HCF3H1.28
5CF3HOMeH1.21
6CF3HHOMe1.11
7CF3HOMeOMe1.10
8HCF3OMeH1.28
9HCF3HOMe1.11
10HCF3OMeOMe1.26
11FFOMeH1.43
12FFHOMe1.40
13FFOMeOMe1.23
14FHOMeOMe1.21
15HFOMeOMe1.12
16CF3OMeCF3H1.19
17CF3OMeOMeH1.55
18CF3OMeHOMe0.95
19CF3OMeOMeOMe1.22
20OMeOMeCF3H0.98
21OBnOBnCF3H1.30
[a] Fluorescence activity ratio as mean of three determinations.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Döring, H.; Kreutzer, D.; Ritter, C.; Hilgeroth, A. Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18. Molecules 2022, 27, 3575. https://doi.org/10.3390/molecules27113575

AMA Style

Döring H, Kreutzer D, Ritter C, Hilgeroth A. Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18. Molecules. 2022; 27(11):3575. https://doi.org/10.3390/molecules27113575

Chicago/Turabian Style

Döring, Henry, David Kreutzer, Christoph Ritter, and Andreas Hilgeroth. 2022. "Correction: Döring et al. Discovery of Novel Symmetrical 1,4-Dihydropyridines as Inhibitors of Multidrug-Resistant Protein (MRP4) Efflux Pump for Anticancer Therapy. Molecules 2021, 26, 18" Molecules 27, no. 11: 3575. https://doi.org/10.3390/molecules27113575

Article Metrics

Back to TopTop